OM:XBRANE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Xbrane Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XBRANE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

XBRANE

4.8%

SE Biotechs

2.7%

SE Market


1 Year Return

154.0%

XBRANE

19.3%

SE Biotechs

16.2%

SE Market

Return vs Industry: XBRANE exceeded the Swedish Biotechs industry which returned 19.3% over the past year.

Return vs Market: XBRANE exceeded the Swedish Market which returned 16.2% over the past year.


Shareholder returns

XBRANEIndustryMarket
7 Day-1.0%4.8%2.7%
30 Day-6.8%-0.7%3.4%
90 Day54.6%16.6%16.1%
1 Year154.0%154.0%20.2%19.3%17.9%16.2%
3 Year81.0%71.6%48.2%44.3%30.4%16.6%
5 Yearn/a79.0%66.6%41.9%13.6%

Price Volatility Vs. Market

How volatile is Xbrane Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xbrane Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XBRANE (SEK76.2) is trading below our estimate of fair value (SEK375.12)

Significantly Below Fair Value: XBRANE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XBRANE is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.

PE vs Market: XBRANE is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XBRANE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XBRANE is overvalued based on its PB Ratio (8.4x) compared to the SE Biotechs industry average (7x).


Next Steps

Future Growth

How is Xbrane Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

67.8%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XBRANE's forecast earnings growth is above the savings rate (0.5%).

Earnings vs Market: Insufficient data to determine if XBRANE's earnings are forecast to grow faster than the Swedish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XBRANE is forecast to have no revenue next year.

High Growth Revenue: XBRANE is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XBRANE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xbrane Biopharma performed over the past 5 years?

-53.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XBRANE is currently unprofitable.

Growing Profit Margin: XBRANE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XBRANE is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.

Accelerating Growth: Unable to compare XBRANE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XBRANE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.4%).


Return on Equity

High ROE: XBRANE has a negative Return on Equity (-130.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xbrane Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: XBRANE's short term assets (SEK217.1M) exceed its short term liabilities (SEK156.8M).

Long Term Liabilities: XBRANE's short term assets (SEK217.1M) exceed its long term liabilities (SEK15.1M).


Debt to Equity History and Analysis

Debt Level: XBRANE is debt free.

Reducing Debt: XBRANE had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XBRANE has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: XBRANE is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Xbrane Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XBRANE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XBRANE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XBRANE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBRANE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XBRANE's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Martin Åmark (40 yo)

5.58yrs

Tenure

kr1,610,000

Compensation

Mr. Martin Åmark serves as the Head of Investor Relation since February 14, 2019 and also serves as Chief Executive Officer of Xbrane Biopharma AB (publ). Mr. Åmark has 8 years of experience from Bain & Co ...


CEO Compensation Analysis

Compensation vs Market: Martin's total compensation ($USD184.24K) is below average for companies of similar size in the Swedish market ($USD465.05K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Martin Åmark
CEO & Head of Investor Relation5.58yrskr1.61m0.80%
SEK 11.8m
Siavash Bashiri
COO & Head of Biosimilars5.58yrskr1.56m0.58%
SEK 8.5m
Samuel Wagner
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Susanna Helgesen
CFO & Investor Relations Officer3.25yrsno data0.077%
SEK 1.1m
David Vikström
Chief Technology Officer6.58yrsno data0.17%
SEK 2.5m
Dina Jurman
Head of Clinical Affairs2.92yrsno data0.0022%
SEK 32.0k
Maria Edebrink
Head of Regulatory Affairs1.58yrsno data0.0076%
SEK 111.2k
Anders Wallström
Head of Manufacturing & Supply Chain1.58yrsno data0.016%
SEK 228.8k
Håkan Yildirim
Head of Intellectual Propertyno datano datano data
Xiaoli Hu
Head of Business Development0.25yrno datano data

3.3yrs

Average Tenure

40yo

Average Age

Experienced Management: XBRANE's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Samuel Wagner
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Björn Nilsson
Member of Scientific Advisory Boardno datano datano data
Mats Thoren
Independent Director0.25yrno datano data
Peter Edman
Independent Director5.58yrskr250.00k0.066%
SEK 971.3k
Giorgio Chirivi
Independent Director4.17yrskr250.00k0.023%
SEK 342.8k
Gunnar Von Heijne
Member of Scientific Advisory Boardno datano datano data
Joen Luirink
Member of Scientific Advisory Boardno datano datano data
David Drew
Member of Scientific Advisory Boardno datano datano data
Ivan Cohen-Tanugi
Independent Director1.25yrskr175.00kno data
Karin Wingstrand
Independent Director5.58yrskr250.00k0.11%
SEK 1.6m
Anders Tullgren
Independent Chairman of the Board2.33yrskr450.00k0.37%
SEK 5.4m
Eva Nilsagård
Independent Director1.25yrskr200.00k0.021%
SEK 304.8k

2.3yrs

Average Tenure

59yo

Average Age

Experienced Board: XBRANE's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XBRANE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25%.


Top Shareholders

Company Information

Xbrane Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xbrane Biopharma AB (publ)
  • Ticker: XBRANE
  • Exchange: OM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr1.468b
  • Shares outstanding: 19.27m
  • Website: https://www.xbrane.com

Number of Employees


Location

  • Xbrane Biopharma AB (publ)
  • BanvaktsvAegen 22
  • Solna
  • Stockholm County
  • 171 48
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBRANEOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKFeb 2016
XBRANSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKFeb 2016

Biography

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/08 20:35
End of Day Share Price2020/08/07 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.